Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

September 8, 2028

Study Completion Date

November 8, 2028

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed Multiple Myeloma transplant-ineligible

Trial Locations (1)

"General Hospital of Athens Alexandra", Athens